Restricted accessResearch articleFirst published online 2019-4
Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials
Multiple N-methyl-d-aspartate (NMDA)-receptor-enhancing agents have demonstrated promising effects for cognition in schizophrenia. However, the results of studies have been conflicting. This updated meta-analysis explored the effect of NMDA-receptor-enhancing agents on cognitive function.
Methods:
We searched PubMed, the Cochrane Collaboration Central Register of Controlled Clinical Trials and Cochrane Systematic Reviews for studies on the effect of NMDA-receptor-enhancing agents on cognitive function in patients with schizophrenia up to September 2018. Double-blind randomised placebo trials with cognition rating scales were included. We pooled studies by using a random-effect model for comparisons with add-on NMDA-receptor-enhancing agents. Cognitive function scores were compared between baseline and subsequent levels, and NMDA-receptor-positive modulators were assessed using the standardised mean difference (SMD) with 95% confidence intervals (CIs). We evaluated statistical heterogeneity through visual inspection of funnel plots and by using the I2 statistic.
Results:
We identified 25 trials with 1951 participants meeting the inclusion criteria. NMDA-receptor-enhancing agents had a small but nonsignificant effect compared with the placebo on overall cognitive function (SMD = 0.068, CI = −0.056 to 0.193, P = 0.283). We identified trials enrolling patients aged between 30 and 39 years old, which reported significant positive effects (SMD: 0.163, 95% CI: 0.016–0.310, P = 0.030). Men were associated with a smaller effect of NMDA-receptor-positive modulators on overall cognitive function. Moreover, subgroup meta-analysis of cognitive domains revealed that N-acetyl cysteine (NAC) had a significant effect on working memory (P-value for interaction = 0.038; SMD = 0.679, CI = 0.397–0.961, P < 0.001).
Conclusions:
Our meta-analysis revealed no significant effect of NMDA-enhancing agents on overall cognition. However, subgroup analysis suggested that NMDAR-enhancing agents may benefit young patients with schizophrenia, and NAC may have an effect on working memory. Additional trials with larger samples are suggested to evaluate these cognitive domains and ascertain the possible mechanisms.
ArakawaMItoY (2007) N-acetylcysteine and neurodegenerative diseases: Basic and clinical pharmacology. Cerebellum6: 308–314.
2.
BerkMCopolovDDeanOet al. (2008) N-acetyl cysteine as a glutathione precursor for schizophrenia – a double-blind, randomized, placebo-controlled trial. Biol Psychiatry64: 361–368.
3.
BuchananRWJavittDCMarderSRet al. (2007) The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry164: 1593–1602.
4.
CainCKMcCueMBelloIet al. (2014) d-Cycloserine augmentation of cognitive remediation in schizophrenia. Schizophr Res153: 177–183.
5.
ChengappaKNTurkinSRDeSantiSet al. (2012) A preliminary, randomized, double-blind, placebo-controlled trial of l-carnosine to improve cognition in schizophrenia. Schizophr Res142: 145–152.
6.
ChoiKHWykesTKurtzMM (2013) Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: Meta-analytical investigation of efficacy. Br J Psychiatry203: 172–178.
7.
ConusPSeidmanLJFournierMet al. (2018) N-acetylcysteine in a double-blind randomized placebo-controlled trial: Toward biomarker-guided treatment in early psychosis. Schizophr Bull44: 317–327.
8.
CoyleJT (1996) The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry3: 241–253.
9.
D’SouzaDCRadhakrishnanRPerryEet al. (2013) Feasibility, safety, and efficacy of the combination of d-serine and computerized cognitive retraining in schizophrenia: An international collaborative pilot study. Neuropsychopharmacology38: 492–503.
10.
DuncanEJSzilagyiSSchwartzMPet al. (2004) Effects of d-cycloserine on negative symptoms in schizophrenia. Schizophr Res71: 239–248.
11.
ForsythJKBachmanPMathalonDHet al. (2017) Effects of augmenting N-methyl- d-aspartate receptor signaling on working memory and experience-dependent plasticity in schizophrenia: An exploratory study using acute d-cycloserine. Schizophr Bull43: 1123–1133.
12.
GoffDCLambertiJSLeonACet al. (2008) A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology33: 465–472.
13.
GoffDCLeahyLBermanIet al. (2001) A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol21: 484–487.
14.
GoffDCTsaiGLevittJet al. (1999) A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry56: 21–27.
15.
GreenMFNuechterleinKHGoldJMet al. (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry56: 301–307.
16.
HafnerHMaurerKLofflerWet al. (2003) Modeling the early course of schizophrenia. Schizophr Bull29: 325–340.
17.
HardinghamGEDoKQ (2016) Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat Rev Neurosci17: 125–134.
18.
HowleyEBestwickMFradleyRet al. (2017) Assessment of the target engagement and d-serine biomarker profiles of the d-amino acid oxidase inhibitors sodium benzoate and PGM030756. Neurochem Res42: 3279–3288.
19.
IbrahimHMHoggAJJrHealyDJet al. (2000) Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry157: 1811–1823.
20.
IwataYNakajimaSSuzukiTet al. (2015) Effects of glutamate positive modulators on cognitive deficits in schizophrenia: A systematic review and meta-analysis of double-blind randomized controlled trials. Mol Psychiatry20: 1151–1160.
21.
JavittDC (2004) Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry9: 984–997.
22.
JavittDCLiedermanECienfuegosAet al. (1999) Panmodal processing imprecision as a basis for dysfunction of transient memory storage systems in schizophrenia. Schizophr Bull25: 763–775.
23.
KellyDLSullivanKMMcEvoyJPet al. (2015) Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol35: 374–381.
24.
KreininABawaknyNRitsnerMS (2017) Adjunctive pregnenolone ameliorates the cognitive deficits in recent-onset schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial. Clin Schizophr Relat Psychoses10: 201–210.
25.
KrystaKMurawiecSKlasikAet al. (2013) Sex-specific differences in cognitive functioning among schizophrenic patients. Psychiatr Danub 25 (Suppl 2): S244–S246.
26.
KrystalJHKarperLPSeibylJPet al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry51: 199–214.
27.
KurachiMTakahashiTSumiyoshiTet al. (2018) Early intervention and a direction of novel therapeutics for the improvement of functional outcomes in schizophrenia: A selective review. Front Psychiatry9: 39.
28.
LaneHYLinCHGreenMFet al. (2013) Add-on treatment of benzoate for schizophrenia: A randomized, double-blind, placebo-controlled trial of d-amino acid oxidase inhibitor. JAMA Psychiatry70: 1267–1275.
29.
LevkovitzYMendlovichSRiwkesSet al. (2010) A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry71: 138–149.
30.
LiFTsienJZ (2009) Memory and the NMDA receptors. N Engl J Med361: 302–303.
31.
LiberatiAAltmanDGTetzlaffJet al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med6: e1000100.
32.
LiebermanJABymasterFPMeltzerHYet al. (2008) Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev60: 358–403.
33.
LinCHChenPKChangYCet al. (2014) Benzoate, a d-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: A randomized, double-blind, placebo-controlled trial. Biol Psychiatry75: 678–685.
34.
LinCHLaneHYTsaiGE (2012) Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav100: 665–677.
35.
LinCHLinCHChangYCet al. (2017a) Sodium benzoate, a d-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial. Biol Psychiatry.
36.
LinCYLiangSYChangYCet al. (2017b) Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. World J Biol Psychiatry18: 357–368.
37.
LiuFGuoXWuRet al. (2014) Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial. Schizophr Res153: 169–176.
38.
MalhotraAKPinalsDAAdlerCMet al. (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology17: 141–150.
39.
MalhotraAKPinalsDAWeingartnerHet al. (1996) NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology14: 301–307.
40.
MarxCEKeefeRSBuchananRWet al. (2009) Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology34: 1885–1903.
41.
MarxCELeeJSubramaniamMet al. (2014) Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology (Berl)231: 3647–3662.
42.
McCarthnyCRDuXWuYCet al. (2018) Investigating the interactive effects of sex steroid hormones and brain-derived neurotrophic factor during adolescence on hippocampal NMDA receptor expression. Int J Endocrinol2018: 7231915.
43.
Meador-WoodruffJHHealyDJ (2000) Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev31: 288–294.
44.
MoherDLiberatiATetzlaffJet al. (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol62: 1006–1012.
45.
OlneyJWFarberNB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry52: 998–1007.
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature511: 421–427.
52.
SchoemakerJHJansenWTSchipperJet al. (2014) The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: Results from the GIANT trial. J Clin Psychopharmacol34: 190–198.
53.
SepehrmaneshZHeidaryMAkashehNet al. (2018) Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry82: 289–296.
54.
SerafiniGPompiliMHaghighatRet al. (2011) Stigmatization of schizophrenia as perceived by nurses, medical doctors, medical students and patients. J Psychiatr Ment Health Nurs18: 576–585.
55.
StefaniMRMoghaddamB (2005) Transient N-methyl-d-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol Psychiatry57: 433–436.
56.
SzilagyiBFerenczyGGKeseruGM (2018) Drug discovery strategies and the preclinical development of d-amino-acid oxidase inhibitors as antipsychotic therapies. Expert Opin Drug Discov13: 973–982.
57.
TanahashiSYamamuraSNakagawaMet al. (2012) Clozapine, but not haloperidol, enhances glial d-serine and l-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol165: 1543–1555.
58.
TsaiGYangPChungLCet al. (1998) d-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry44: 1081–1089.
59.
TsaiGELinPY (2010) Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des16: 522–537.
60.
TsaiGEYangPChungLCet al. (1999) d-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry156: 1822–1825.
61.
WeiserMHeresco-LevyUDavidsonMet al. (2012) A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry73: e728–e734.
62.
WimoAJonssonLGustavssonAet al. (2011) The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int J Geriatr Psychiatry26: 825–832.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
